PMID- 33674243
OWN - NLM
STAT- MEDLINE
DCOM- 20211206
LR  - 20211214
IS  - 2531-0437 (Electronic)
IS  - 2531-0429 (Linking)
VI  - 27
IP  - 5
DP  - 2021 Sep-Oct
TI  - Markers of cardiovascular risk and their reversibility with acute oxygen therapy 
      in Kyrgyz highlanders with high altitude pulmonary hypertension.
PG  - 394-402
LID - S2531-0437(21)00049-0 [pii]
LID - 10.1016/j.pulmoe.2021.02.001 [doi]
AB  - BACKGROUND: High altitude pulmonary hypertension (HAPH), a chronic altitude 
      related illness, is associated with hypoxemia, dyspnea and reduced exercise 
      performance. We evaluated ECG and pulse wave-derived markers of cardiovascular 
      risk in highlanders with HAPH (HAPH+) in comparison to healthy highlanders (HH) 
      and lowlanders (LL) and the effects of hyperoxia. METHODS: We studied 34 HAPH+ 
      and 54 HH at Aksay (3250m), and 34 LL at Bishkek (760m), Kyrgyzstan. Mean 
      pulmonary artery pressure by echocardiography was mean+/-SD 34+/-3, 22+/-5, 16+/-4mmHg, 
      respectively (p<0.05 all comparisons). During quiet rest, breathing room air or 
      oxygen in randomized order, we measured heart-rate adjusted QT interval (QTc), an 
      ECG-derived marker of increased cardiovascular mortality, and arterial stiffness 
      index (SI), a marker of cardiovascular disease derived from pulse oximetry 
      plethysmograms. RESULTS: Pulse oximetry in HAPH+, HH and LL was, mean+/-SD, 88+/-4, 
      92+/-2 and 95+/-2%, respectively (p<0.05 vs HAPH+, both comparisons). QTc in HAPH+, 
      HH and LL was 422+/-24, 405+/-27, 400+/-28ms (p<0.05 HAPH+ vs. others); corresponding 
      SI was 10.5+/-1.9, 8.4+/-2.6, 8.5+/-2.0m/s, heart rate was 75+/-8, 68+/-8, 70+/-10 bpm 
      (p<0.05, corresponding comparisons HAPH+ vs. others). In regression analysis, 
      HAPH+ was an independent predictor of increased QTc and SI when controlled for 
      several confounders. Oxygen breathing increased SI in HH but not in HAPH+, and 
      reduced QTc in all groups. CONCLUSIONS: Our data suggest that HAPH+ but not HH 
      may be at increased risk of cardiovascular mortality and morbidity compared to 
      LL. The lack of a further increase of the elevated SI during hyperoxia in HAPH+ 
      may indicate dysfunctional control of vascular tone and/or remodelling.
CI  - Copyright (c) 2021 Sociedade Portuguesa de Pneumologia. Published by Elsevier 
      Espana, S.L.U. All rights reserved.
FAU - Furian, M
AU  - Furian M
AD  - Pulmonary Division and Sleep Disorders Center, University Hospital of Zurich, 
      Raemistrasse 100, 8091 Zurich, Switzerland.
FAU - Latshang, T D
AU  - Latshang TD
AD  - Pulmonary Division and Sleep Disorders Center, University Hospital of Zurich, 
      Raemistrasse 100, 8091 Zurich, Switzerland.
FAU - Aeschbacher, S S
AU  - Aeschbacher SS
AD  - Pulmonary Division and Sleep Disorders Center, University Hospital of Zurich, 
      Raemistrasse 100, 8091 Zurich, Switzerland.
FAU - Sheraliev, U
AU  - Sheraliev U
AD  - National Center for Cardiology and Internal Medicine, Department of Respiratory 
      Medicine, 3 Togolok Moldo Str., Bishkek 720040, Kyrgyzstan.
FAU - Marazhapov, N H
AU  - Marazhapov NH
AD  - National Center for Cardiology and Internal Medicine, Department of Respiratory 
      Medicine, 3 Togolok Moldo Str., Bishkek 720040, Kyrgyzstan.
FAU - Mirrakhimov, E
AU  - Mirrakhimov E
AD  - National Center for Cardiology and Internal Medicine, Department of Respiratory 
      Medicine, 3 Togolok Moldo Str., Bishkek 720040, Kyrgyzstan.
FAU - Ulrich, S
AU  - Ulrich S
AD  - Pulmonary Division and Sleep Disorders Center, University Hospital of Zurich, 
      Raemistrasse 100, 8091 Zurich, Switzerland.
FAU - Sooronbaev, T M
AU  - Sooronbaev TM
AD  - National Center for Cardiology and Internal Medicine, Department of Respiratory 
      Medicine, 3 Togolok Moldo Str., Bishkek 720040, Kyrgyzstan.
FAU - Bloch, K E
AU  - Bloch KE
AD  - Pulmonary Division and Sleep Disorders Center, University Hospital of Zurich, 
      Raemistrasse 100, 8091 Zurich, Switzerland. Electronic address: 
      Konrad.bloch@usz.ch.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20210303
PL  - Spain
TA  - Pulmonology
JT  - Pulmonology
JID - 101723786
RN  - S88TT14065 (Oxygen)
RN  - Pulmonary edema of mountaineers
SB  - IM
MH  - Adult
MH  - Aged
MH  - Altitude Sickness/*therapy
MH  - Cardiovascular Diseases/blood/epidemiology
MH  - Death, Sudden, Cardiac
MH  - Echocardiography
MH  - Female
MH  - Heart Disease Risk Factors
MH  - Heart Rate/physiology
MH  - Humans
MH  - *Hyperoxia
MH  - Hypertension, Pulmonary/*therapy
MH  - Hypoxia
MH  - Male
MH  - Middle Aged
MH  - Oxygen/*therapeutic use
MH  - Risk Factors
OTO - NOTNLM
OT  - Highlanders
OT  - Hyperoxia
OT  - Hypoxia
OT  - QT prolongation
OT  - Sudden cardiac death
EDAT- 2021/03/07 06:00
MHDA- 2021/12/15 06:00
CRDT- 2021/03/06 05:34
PHST- 2020/10/14 00:00 [received]
PHST- 2021/02/03 00:00 [revised]
PHST- 2021/02/03 00:00 [accepted]
PHST- 2021/03/07 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
PHST- 2021/03/06 05:34 [entrez]
AID - S2531-0437(21)00049-0 [pii]
AID - 10.1016/j.pulmoe.2021.02.001 [doi]
PST - ppublish
SO  - Pulmonology. 2021 Sep-Oct;27(5):394-402. doi: 10.1016/j.pulmoe.2021.02.001. Epub 
      2021 Mar 3.